Pulmatrix Inc (PULM)

Currency in USD
5.6100
-0.4000(-6.66%)
Closed·
After Hours
5.6200+0.0100(+0.18%)
·
PULM Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 12 days
Fair Value
Day's Range
5.60006.1465
52 wk Range
1.780010.4000
Key Statistics
Prev. Close
6.022
Open
6.01
Day's Range
5.6-6.1465
52 wk Range
1.78-10.4
Volume
21.35K
Average Volume (3m)
30.66K
1-Year Change
205.69%
Book Value / Share
1.96
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PULM Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in oversold territory

Pulmatrix Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Pulmatrix Inc Company Profile

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor compounds. The company was founded in 2003 and is headquartered in Framingham, Massachusetts.

Compare PULM to Peers and Sector

Metrics to compare
PULM
Peers
Sector
Relationship
P/E Ratio
−1.7x−0.4x−0.5x
PEG Ratio
0.050.000.00
Price/Book
2.9x0.0x2.6x
Price / LTM Sales
10.7x1.4x3.2x
Upside (Analyst Target)
-376.2%41.9%
Fair Value Upside
Unlock14.9%4.3%Unlock

Earnings

Latest Release
May 19, 2025
EPS / Forecast
-0.50 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

PULM Income Statement

People Also Watch

271.20
AVAV
-0.59%
242.33
LEU
+5.59%
51.030
SMR
+6.65%
709.32
AXON
+0.58%
93.27
ATI
-0.87%

FAQ

What Stock Exchange Does Pulmatrix Trade On?

Pulmatrix is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Pulmatrix?

The stock symbol for Pulmatrix is "PULM."

What Is the Pulmatrix Market Cap?

As of today, Pulmatrix market cap is 20.85M.

What Is Pulmatrix's Earnings Per Share (TTM)?

The Pulmatrix EPS (TTM) is -3.34.

When Is the Next Pulmatrix Earnings Date?

Pulmatrix will release its next earnings report on 05 Aug 2025.

From a Technical Analysis Perspective, Is PULM a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Pulmatrix Stock Split?

Pulmatrix has split 3 times.

How Many Employees Does Pulmatrix Have?

Pulmatrix has 2 employees.

What is the current trading status of Pulmatrix (PULM)?

As of 24 Jul 2025, Pulmatrix (PULM) is trading at a price of 5.61, with a previous close of 6.02. The stock has fluctuated within a day range of 5.60 to 6.15, while its 52-week range spans from 1.78 to 10.40.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.